ProCE Banner Activity

COMFORT-1: Final 5-Yr Analysis of Ruxolitinib in Int- or High-Risk Myelofibrosis

Slideset Download
Conference Coverage
Long-term analysis shows durable reductions in splenomegaly and significantly prolonged survival with ruxolitinib in patients with intermediate- or high-risk myelofibrosis.

Released: June 07, 2016

Expiration: June 06, 2017

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Ariad

Bayer Healthcare Pharma

Celgene

Genentech Roche Virology

Incyte

Merck Oncology

Taiho Pharmaceuticals